{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T07:35:37Z","timestamp":1740123337763,"version":"3.37.3"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T00:00:00Z","timestamp":1518825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001691","name":"Japan Society for the Promotion of Science","doi-asserted-by":"publisher","award":["15K20967"],"award-info":[{"award-number":["15K20967"]}],"id":[{"id":"10.13039\/501100001691","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2018,6]]},"DOI":"10.1007\/s10637-018-0572-2","type":"journal-article","created":{"date-parts":[[2018,2,17]],"date-time":"2018-02-17T01:34:13Z","timestamp":1518831253000},"page":"487-495","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Drug approval based on randomized phase 3 trials for relapsed malignancy: analysis of oncologic drugs granted accelerated approval, publications and clinical trial databases"],"prefix":"10.1007","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8401-6074","authenticated-orcid":false,"given":"Sumimasa","family":"Nagai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiya","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,2,17]]},"reference":[{"key":"572_CR1","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1093\/jnci\/djr062","volume":"103","author":"JR Johnson","year":"2011","unstructured":"Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R (2011) Accelerated approval of oncology products: the food and drug administration experience. J Natl Cancer Inst 103:636\u2013644","journal-title":"J Natl Cancer Inst"},{"key":"572_CR2","doi-asserted-by":"publisher","first-page":"5172","DOI":"10.1158\/1078-0432.CCR-12-1135","volume":"18","author":"H Gaddipati","year":"2012","unstructured":"Gaddipati H, Liu K, Pariser A, Pazdur R (2012) Rare cancer trial design: lessons from FDA approvals. Clin Cancer Res 18:5172\u20135178","journal-title":"Clin Cancer Res"},{"key":"572_CR3","doi-asserted-by":"publisher","first-page":"1404","DOI":"10.1200\/JCO.2003.08.072","volume":"21","author":"JR Johnson","year":"2003","unstructured":"Johnson JR, Williams G, Pazdur R (2003) End points and United States Food and Drug Administration approval of oncology drugs. J Clin Oncol 21:1404\u20131411","journal-title":"J Clin Oncol"},{"key":"572_CR4","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1093\/jnci\/djp515","volume":"102","author":"R Sridhara","year":"2010","unstructured":"Sridhara R, Johnson JR, Justice R, Keegan P, Chakravarty A, Pazdur R (2010) Review of oncology and hematology drug product approvals at the US Food and Drug Administration between July 2005 and December 2007. J Natl Cancer Inst 102:230\u2013243","journal-title":"J Natl Cancer Inst"},{"key":"572_CR5","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1002\/cpt.86","volume":"97","author":"R Simon","year":"2015","unstructured":"Simon R, Blumenthal GM, Rothenberg ML et al (2015) The role of nonrandomized trials in the evaluation of oncology drugs. Clin Pharmacol Ther 97:502\u2013507","journal-title":"Clin Pharmacol Ther"},{"key":"572_CR6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/bjh.14047","volume":"174","author":"S Nagai","year":"2016","unstructured":"Nagai S, Ozawa K (2016) Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US. Br J Haematol 174:249\u2013254","journal-title":"Br J Haematol"},{"key":"572_CR7","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software 'EZR' for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"572_CR8","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1200\/JCO.2012.48.1887","volume":"31","author":"D Przepiorka","year":"2013","unstructured":"Przepiorka D, Deisseroth A, Kane R, Kaminskas E, Farrell AT, Pazdur R (2013) Gemtuzumab ozogamicin. J Clin Oncol 31:1699\u20131700","journal-title":"J Clin Oncol"},{"key":"572_CR9","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","volume":"28","author":"C Gisselbrecht","year":"2010","unstructured":"Gisselbrecht C, Glass B, Mounier N et al (2010) Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era. J Clin Oncol 28:4184\u20134190","journal-title":"J Clin Oncol"},{"key":"572_CR10","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1182\/blood-2007-09-111708","volume":"111","author":"JA Thompson","year":"2008","unstructured":"Thompson JA, Fisher RI, Leblanc M et al (2008) Total body irradiation, etoposide, cyclophosphamide, and autologous peripheral blood stem-cell transplantation followed by randomization to therapy with interleukin-2 versus observation for patients with non-Hodgkin lymphoma: results of a phase 3 randomized trial by the southwest oncology group (SWOG 9438). Blood 111:4048\u20134054","journal-title":"Blood"},{"key":"572_CR11","doi-asserted-by":"publisher","first-page":"4462","DOI":"10.1200\/JCO.2012.41.9416","volume":"30","author":"C Gisselbrecht","year":"2012","unstructured":"Gisselbrecht C, Schmitz N, Mounier N et al (2012) Rituximab maintenance therapy after autologous stem-cell transplantation in patients with relapsed CD20(+) diffuse large B-cell lymphoma: final analysis of the collaborative trial in relapsed aggressive lymphoma. J Clin Oncol 30:4462\u20134469","journal-title":"J Clin Oncol"},{"key":"572_CR12","doi-asserted-by":"publisher","first-page":"1662","DOI":"10.1200\/JCO.2012.45.9453","volume":"31","author":"JM Vose","year":"2013","unstructured":"Vose JM, Carter S, Burns LJ et al (2013) Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. J Clin Oncol 31:1662\u20131668","journal-title":"J Clin Oncol"},{"key":"572_CR13","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1002\/cncr.27418","volume":"118","author":"A Shimoni","year":"2012","unstructured":"Shimoni A, Avivi I, Rowe JM et al (2012) Phase III randomized study of rituximab\/carmustine, etoposide, cytarabine, and melphalan (BEAM) compared with iodine-131 tositumomab\/BEAM with autologous hematopoietic cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 trial. Cancer 118:4706\u20134714","journal-title":"Cancer"},{"key":"572_CR14","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","volume":"32","author":"M Crump","year":"2014","unstructured":"Crump M, Kuruvilla J, Couban S et al (2014) Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12. J Clin Oncol 32:3490\u20133496","journal-title":"J Clin Oncol"},{"key":"572_CR15","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1016\/S1470-2045(12)70212-7","volume":"13","author":"R Pettengell","year":"2012","unstructured":"Pettengell R, Coiffier B, Narayanan G et al (2012) Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol 13:696\u2013706","journal-title":"Lancet Oncol"},{"key":"572_CR16","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(15)00447-7","volume":"17","author":"M Rummel","year":"2016","unstructured":"Rummel M, Kaiser U, Balser C et al (2016) Study group indolent lymphomas: Bendamustine plus rituximab versus fludarabine plus rituximab for patients with relapsed indolent and mantle-cell lymphomas: a multicentre, randomised, open-label, non-inferiority phase 3 trial. Lancet Oncol 17:57\u201366","journal-title":"Lancet Oncol"},{"key":"572_CR17","doi-asserted-by":"publisher","first-page":"1624","DOI":"10.1200\/JCO.2012.47.1862","volume":"31","author":"R Pettengell","year":"2013","unstructured":"Pettengell R, Schmitz N, Gisselbrecht C et al (2013) Rituximab purging and\/or maintenance in patients undergoing autologous transplantation for relapsed follicular lymphoma: a prospective randomized trial from the lymphoma working party of the European group for blood and marrow transplantation. J Clin Oncol 31:1624\u20131630","journal-title":"J Clin Oncol"},{"key":"572_CR18","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1200\/JCO.2002.11.068","volume":"20","author":"RJ Klasa","year":"2002","unstructured":"Klasa RJ, Meyer RM, Shustik C et al (2002) Randomized phase III study of fludarabine phosphate versus cyclophosphamide, vincristine, and prednisone in patients with recurrent low-grade non-Hodgkin's lymphoma previously treated with an alkylating agent or alkylator-containing regimen. J Clin Oncol 20:4649\u20134654","journal-title":"J Clin Oncol"},{"key":"572_CR19","doi-asserted-by":"publisher","first-page":"3064","DOI":"10.1182\/blood-2004-04-1323","volume":"104","author":"R Forstpointner","year":"2004","unstructured":"Forstpointner R, Dreyling M, Repp R et al (2004) German low-grade lymphoma study group: the addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German low-grade lymphoma study group. Blood 104:3064\u20133071","journal-title":"Blood"},{"key":"572_CR20","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S1470-2045(11)70150-4","volume":"12","author":"B Coiffier","year":"2011","unstructured":"Coiffier B, Osmanov EA, Hong X et al (2011) LYM-3001 study investigators: Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naive or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. Lancet Oncol 12:773\u2013784","journal-title":"Lancet Oncol"},{"key":"572_CR21","doi-asserted-by":"publisher","first-page":"2853","DOI":"10.1200\/JCO.2009.26.5827","volume":"28","author":"MH van Oers","year":"2010","unstructured":"van Oers MH, Van Glabbeke M, Giurgea L et al (2010) Rituximab maintenance treatment of relapsed\/resistant follicular non-Hodgkin's lymphoma: long-term outcome of the EORTC 20981 phase III randomized intergroup study. J Clin Oncol 28:2853\u20132858","journal-title":"J Clin Oncol"},{"key":"572_CR22","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1200\/JCO.2003.10.023","volume":"21","author":"HC Schouten","year":"2003","unstructured":"Schouten HC, Qian W, Kvaloy S et al (2003) High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial. J Clin Oncol 21:3918\u20133927","journal-title":"J Clin Oncol"},{"key":"572_CR23","doi-asserted-by":"publisher","first-page":"2453","DOI":"10.1200\/JCO.2002.11.076","volume":"20","author":"TE Witzig","year":"2002","unstructured":"Witzig TE, Gordon LI, Cabanillas F et al (2002) Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma. J Clin Oncol 20:2453\u20132463","journal-title":"J Clin Oncol"},{"key":"572_CR24","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3109\/10428194.2014.927461","volume":"56","author":"RC Quackenbush","year":"2015","unstructured":"Quackenbush RC, Horner TJ, Williams VC, Giampietro P, Lin TS (2015) Patients with relapsed follicular lymphoma treated with rituximab versus tositumomab and iodine I-131 tositumomab. Leuk Lymphoma 56:779\u2013781","journal-title":"Leuk Lymphoma"},{"key":"572_CR25","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1016\/S1470-2045(16)30097-3","volume":"17","author":"LH Sehn","year":"2016","unstructured":"Sehn LH, Chua N, Mayer J et al (2016) Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial. Lancet Oncol 17:1081\u20131093","journal-title":"Lancet Oncol"},{"key":"572_CR26","doi-asserted-by":"publisher","first-page":"3822","DOI":"10.1200\/JCO.2008.20.7977","volume":"27","author":"G Hess","year":"2009","unstructured":"Hess G, Herbrecht R, Romaguera J et al (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822\u20133829","journal-title":"J Clin Oncol"},{"key":"572_CR27","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1016\/S0140-6736(15)00667-4","volume":"387","author":"M Dreyling","year":"2016","unstructured":"Dreyling M, Jurczak W, Jerkeman M et al (2016) Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. Lancet 387:770\u2013778","journal-title":"Lancet"},{"key":"572_CR28","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1016\/S0140-6736(02)08938-9","volume":"359","author":"N Schmitz","year":"2002","unstructured":"Schmitz N, Pfistner B, Sextro M et al (2002) German Hodgkin's lymphoma study group.; lymphoma working Party of the European Group for blood and marrow transplantation: aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 359:2065\u20132071","journal-title":"Lancet"},{"key":"572_CR29","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","volume":"385","author":"CH Moskowitz","year":"2015","unstructured":"Moskowitz CH, Nademanee A, Masszi T et al (2015) AETHERA study group: Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 385:1853\u20131862","journal-title":"Lancet"},{"key":"572_CR30","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1056\/NEJMoa1509277","volume":"375","author":"HM Kantarjian","year":"2016","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M et al (2016) Inotuzumab Ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med 375:740\u2013753","journal-title":"N Engl J Med"},{"key":"572_CR31","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1001\/jamainternmed.2015.2829","volume":"175","author":"V Prasad","year":"2015","unstructured":"Prasad V, Kim C, Burotto M, Vandross A (2015) The strength of association between surrogate end points and survival in oncology: a systematic review of trial-level meta-analyses. JAMA Intern Med 175:1389\u20131398","journal-title":"JAMA Intern Med"},{"key":"572_CR32","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j1680","volume":"357","author":"AM Pease","year":"2017","unstructured":"Pease AM, Krumholz HM, Downing NS, Aminawung JA, Shah ND, Ross JS (2017) Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review. BMJ 357:j1680. https:\/\/doi.org\/10.1136\/bmj.j1680","journal-title":"BMJ"},{"key":"572_CR33","doi-asserted-by":"publisher","first-page":"1854","DOI":"10.1001\/jama.2017.5150","volume":"317","author":"NS Downing","year":"2017","unstructured":"Downing NS, Shah ND, Aminawung JA et al (2017) Postmarket safety events among novel therapeutics approved by the US Food and Drug Administration between 2001 and 2010. JAMA 317:1854\u20131863","journal-title":"JAMA"},{"key":"572_CR34","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1001\/jama.2013.282034","volume":"311","author":"NS Downing","year":"2014","unstructured":"Downing NS, Aminawung JA, Shah ND, Krumholz HM, Ross JS (2014) Clinical trial evidence supporting FDA approval of novel therapeutic agents, 2005-2012. JAMA 311:368\u2013377","journal-title":"JAMA"},{"key":"572_CR35","doi-asserted-by":"publisher","first-page":"2320","DOI":"10.1001\/jama.2011.769","volume":"305","author":"AS Kesselheim","year":"2011","unstructured":"Kesselheim AS, Myers JA, Avorn J (2011) Characteristics of clinical trials to support approval of orphan vs nonorphan drugs for cancer. JAMA 305:2320\u20132326","journal-title":"JAMA"},{"key":"572_CR36","doi-asserted-by":"publisher","first-page":"1992","DOI":"10.1001\/jamainternmed.2015.5868","volume":"175","author":"C Kim","year":"2015","unstructured":"Kim C, Prasad V (2015) Cancer drugs approved on the basis of a surrogate end point and subsequent overall survival: an analysis of 5 years of US Food and Drug Administration approvals. JAMA Intern Med 175:1992\u20131994","journal-title":"JAMA Intern Med"},{"key":"572_CR37","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1001\/jamainternmed.2016.7777","volume":"177","author":"SR Bauer","year":"2017","unstructured":"Bauer SR, Redberg RF (2017) Improving the accelerated pathway to cancer drug approvals. JAMA Intern Med 177:278","journal-title":"JAMA Intern Med"},{"key":"572_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h4679","volume":"351","author":"B Wang","year":"2015","unstructured":"Wang B, Kesselheim AS (2015) Characteristics of efficacy evidence supporting approval of supplemental indications for prescription drugs in United States, 2005-14: systematic review. BMJ 351:h4679. https:\/\/doi.org\/10.1136\/bmj.h4679","journal-title":"BMJ"},{"key":"572_CR39","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1056\/NEJMsb1609216","volume":"375","author":"RE Sherman","year":"2016","unstructured":"Sherman RE, Anderson SA, Dal Pan GJ et al (2016) Real-world evidence - what is it and what can it tell us? N Engl J Med 375:2293\u20132297","journal-title":"N Engl J Med"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-018-0572-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-018-0572-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T18:21:07Z","timestamp":1678558867000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-018-0572-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,17]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,6]]}},"alternative-id":["572"],"URL":"https:\/\/doi.org\/10.1007\/s10637-018-0572-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"type":"print","value":"0167-6997"},{"type":"electronic","value":"1573-0646"}],"subject":[],"published":{"date-parts":[[2018,2,17]]},"assertion":[{"value":"5 January 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Nagai was paid as a consultant at Takara Bio Inc. Dr. Ozawa received research funding from Takara Bio Inc. and was paid as a consultant at Celgene Japan. These were not related to this work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This article does not contain any studies with human participants or animals performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}